Insider Trading Activity For Brainstorm Cell Therapeutics (NASDAQ:BCLI)
June Sherie Almenoff , Director of Brainstorm Cell Therapeutics (NASDAQ:BCLI) reportedly Bought 5,700 shares of the company’s stock at an average price of 3.5 for a total transaction amount of $19,950.00 SEC Form
Insider Trading History For Brainstorm Cell Therapeutics (NASDAQ:BCLI)
Analyst Ratings History For Brainstorm Cell Therapeutics (NASDAQ:BCLI)
- On 3/8/2018 Maxim Group Set Price Target of rating Buy with a price target of $9.00
Recent Trading Activity for Brainstorm Cell Therapeutics (NASDAQ:BCLI)
Shares of Brainstorm Cell Therapeutics closed the previous trading session at 3.30 down -0.05 1.49% with 8113 shares trading hands.